Clinical trials
Gastric Cancer or Gastroesophageal Junction Adenocarcinoma clinical trials
Below are recruiting gastric cancer or gastroesophageal junction adenocarcinoma clinical trials, each written for real people, not researchers. We’re tracking 1,144 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05757336RecruitingPhase 2
Study drug mix for unresectable gallbladder cancer
This Phase 2 trial tests a combination of cancer medicines (gemcitabine plus albumin-paclitaxel) along with immune therapy (sintilimab) and a blood-vessel–targeting drug (bevacizumab). It’s for people with gallbladder cancer that can’t be removed by surgery, to see if the treatment controls the cancer and improves outcomes.
ShanghaiAges 18–75 - NCT05841472RecruitingPhase 2
Camrelizumab plus chemo for advanced lung cancer without EGFR or ALK
This Phase 2 trial tests whether the immunotherapy drug camrelizumab, combined with pemetrexed and carboplatin, can work better as first treatment for advanced lung cancer that has no EGFR or ALK gene changes. You may be able to join if you have measurable disease, good enough organ function, and meet other safety rules for immune treatment.
AnamAges 19–80 - NCT06059560Recruiting
Nutrition program for people with cancer having surgery
This study is testing a special nutritional program for people with certain types of cancer who are having surgery. It aims to help improve nutrition and recovery after the operation.
Shenyang, LiaoningAges 18–80 - NCT06118762RecruitingPhase 4
Study of fruquintinib plus raltitrexed for advanced colorectal cancer
This trial tests two drugs, fruquintinib and raltitrexed, for people with metastatic colorectal cancer that has stopped responding to or is no longer tolerable after standard treatments like fluorouracil, oxaliplatin, and irinotecan. The goal is to see if this combination can help shrink or control the cancer.
Nanchang, JiangxiAges 18 years+ - NCT05444270Recruiting
Radiation and medicine for recurrent ovarian cancer
This trial studies a “salvage” (next-line) cancer treatment for recurrent epithelial ovarian cancer, with or without a focused type of radiation. It may help by shrinking or controlling limited spots of cancer that have come back after prior standard treatment.
SeoulAges 19 years+ - NCT06242067RecruitingPhase 2
Second-line treatment for advanced colorectal cancer
This trial tests a new treatment for people with advanced colorectal cancer that has spread or come back after initial chemotherapy. It is for those who have already received standard first-line therapy and are now looking for a second treatment option.
Jinan, ShandongAges 18–75 - NCT04886635Recruiting
Surgery timing after chemoradiation for esophageal cancer
This study looks at whether having surgery at the right time after chemoradiation improves outcomes for people with esophageal cancer. You might qualify if you have had (or are planning) chemoradiation and then are going to have surgery to remove the tumor.
Rotterdam, South HollandAges 18 years+ - NCT07854600RecruitingPhase 2
Ivonescimab plus chemotherapy before surgery for bile duct cancer
This trial tests a new drug combination given before surgery to shrink bile duct cancer tumors, potentially making surgery more successful. It is for patients whose cancer is locally advanced or has spread to only a few places.
Beijing, Beijing MunicipalityAges 18–80 - NCT06329908RecruitingEarly Phase 1
Dendritic cell vaccine plus immunotherapy for resistant lung cancer
This trial tests a new treatment combining a dendritic cell vaccine (a type of immune therapy that trains your body to fight cancer) with additional immunotherapy drugs. It is for people with advanced lung cancer that has stopped responding to standard immunotherapy.
Chengdu, SichuanAges 18–85 - NCT06338683RecruitingPhase 3
Olanzapine for advanced upper digestive and lung cancer survival
This study tests whether a medicine called olanzapine can improve survival in people with advanced cancers of the upper digestive system or lungs. Olanzapine may help with appetite and weight, which are common problems in these cancers.
Xining, QinghaiAges 18–80 - NCT06361316Recruiting
Liposomal irinotecan with chemo after pancreatic cancer surgery
This trial tests a combination of three chemotherapy medicines (liposomal irinotecan, oxaliplatin, and tegafur) given after surgery to remove pancreatic cancer. The goal is to see if this treatment helps prevent the cancer from coming back.
Nanjing, JiangsuAges 18–75 - NCT05817214RecruitingPhase 2
Immunotherapy plus targeted drug for advanced cervical cancer
This Phase 2 trial tests cadonilimab (an immunotherapy medicine) combined with anlotinib (a targeted drug) for advanced or recurrent cervical cancer that has already been treated. It may help shrink tumors or slow cancer growth, especially if the cancer has a measurable area doctors can track.
Wuhan, HubeiAges 18–75 - NCT06361043Recruiting
Adaptive radiation therapy for esophageal cancer
This study tests a new, more precise type of radiation therapy for esophageal cancer that adjusts the treatment in real time using a special CT scan. It aims to deliver a stronger dose to the tumor while sparing healthy tissue, which could improve outcomes.
BernAges 18 years+ - NCT06368063RecruitingPhase 4
Huaier granules after pancreatic cancer surgery
This trial tests whether a Chinese herbal medicine called Huaier granules works better than standard chemotherapy for people with pancreatic cancer that was removed by surgery. Participants can choose to take Huaier granules or standard chemotherapy, and researchers will compare outcomes.
Xi'an, ShannxiAges 18–80 - NCT06478108RecruitingPhase 2/Phase 3
Software-guided multi-immunotherapy for solid tumors
This trial tests a new software-guided approach to deliver multiple immunotherapy drugs directly into the liver for people with solid tumors. It aims to see if this method can shrink tumors and improve survival.
Guangzhou, GuangdongAges 18–75 - NCT06483347RecruitingPhase 2
Immunotherapy combo for inoperable lung cancer
This trial tests a combination of immunotherapy drugs (checkpoint inhibitors) delivered directly into the liver along with standard treatment, as a first option for people with inoperable lung cancer. It aims to see if this approach can help shrink tumors and improve outcomes.
Guangzhou, GuangdongAges 18–75 - NCT06525428RecruitingPhase 2
Adding radiation and immunotherapy to standard care for advanced colorectal cancer
This trial is testing a combination of standard chemotherapy, radiation therapy, and an immunotherapy drug (toripalimab) for people with metastatic colorectal cancer. It aims to see if adding radiation therapy and immunotherapy can help shrink tumors and improve outcomes.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07799935Recruiting
Tumor ablation after chemo for advanced pancreatic cancer
This study tests a procedure called irreversible electroporation (IRE), which uses electric pulses to destroy cancer cells, after chemotherapy for advanced pancreatic cancer that hasn't spread. It aims to control the tumor and improve outcomes in people who are not eligible for surgery.
Tianjin, Tianjin MunicipalityAges 18–75 - NCT06289751RecruitingPhase 2
Chemo-immunotherapy before surgery for stage IB2 cervical cancer
This trial tests if giving chemotherapy plus an immunotherapy drug before surgery can help shrink tumors and improve outcomes for patients with stage IB2 cervical cancer that has not been treated yet. It might be an option if you have a specific type of cervical cancer that shows a certain protein (PD-L1) on your tumor cells.
Wuhan, HubeiAges 18–70 - NCT05994521Recruiting
Preventing stomach blockage in advanced periampullary cancer
This study tests a new procedure (EUS-guided gastroenterostomy) to prevent stomach blockage in people with advanced cancers near the pancreas. It may help you avoid future vomiting and eating problems by placing a small tube between your stomach and intestine using a thin, flexible scope.
MontrealAges 18–85 - NCT07724223RecruitingPhase 2
Combination targeted therapy for advanced colorectal cancer
This trial tests a combination of two targeted drugs (fruquintinib and a drug that targets EGFR) as a third-line treatment for people with a specific type of colorectal cancer that has not responded to previous therapies. It may offer a new option for patients whose tumors are 'wild-type' for certain genes.
Beijing, Beijing MunicipalityAges 18–75 - NCT07718490RecruitingPhase 2
Immunotherapy with simvastatin and chemo for advanced colorectal cancer
This trial tests a new combination of immunotherapy, simvastatin (a cholesterol drug), and standard chemotherapy for advanced colorectal cancer that has not been treated before. The goal is to see if adding simvastatin can help the immune system fight the cancer better.
Nanjing, JiangsuAges 18–75 - NCT07704658RecruitingPhase 4
Pralsetinib drug interaction study for advanced solid tumors
This trial tests how pralsetinib interacts with other drugs in people with advanced solid tumors that have a specific RET gene change. It aims to find the right dose and safety profile.
Logroño, La RiojaAges 18 years+ - NCT07696793RecruitingPhase 4
Simethicone colonoscopy prep for cancer screening
This trial tests a colonoscopy preparation drink that contains simethicone (a gas-relief ingredient) to see if it works better than standard prep for people who are already scheduled for a screening colonoscopy after a positive stool test. It may help make the procedure more comfortable and effective.
Barcelona, BarcelonaAges 50–69
Hear when a new Gastric Cancer or Gastroesophageal Junction Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for gastric cancer or gastroesophageal junction adenocarcinoma?
- Yes. Clin2 currently lists 1,144 recruiting gastric cancer or gastroesophageal junction adenocarcinoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a gastric cancer or gastroesophageal junction adenocarcinoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a gastric cancer or gastroesophageal junction adenocarcinoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Gastric Cancer, Gastroesophageal Junction Cancer
- Gastric / Gastroesophageal Junction Adenocarcinoma
- Gastric or Gastroesophageal Junction Adenocarcinoma
- AFP Gastric or Gastroesophageal Junction Adenocarcinoma
- Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma
- Gastroesophageal Junction Adenocarcinoma
- Gastroesophageal-junction Cancer
- Metastatic Gastroesophageal Junction Adenocarcinoma
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.